 WESTLAKE VILLAGE, Calif., Nov. 19, 2020 GLOBE NEWSWIRE -- MannKind Corporation NASDAQ:MNKD today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. 